Halozyme Therapeutics
HALO
#1963
Rank
$6.85 B
Marketcap
$50.71
Share price
-4.82%
Change (1 day)
58.62%
Change (1 year)

Operating Margin for Halozyme Therapeutics (HALO)

Operating Margin as of January 2023 (TTM): 40.11%

According to Halozyme Therapeutics's latest financial reports and stock price the company's current Operating Margin is 40.11%. At the end of 2021 the company had an Operating Margin of 56.06%.

Operating Margin history for Halozyme Therapeutics from 2002 to 2022

Operating Margin at the end of each year

Year Operating Margin Change
202156.06%16.02%
202048.32%-231.08%
2019-36.86%-29.84%
2018-52.54%-370.02%
201719.46%-128.02%
2016-69.44%190.97%
2015-23.86%-73.71%
2014-90.76%-40.42%
2013-152.33%20.4%
2012-126.53%257.7%
2011-35.37%-90.95%
2010-390.79%-8.46%
2009-426.88%-23.2%
2008-555.87%-24.97%
2007-740.89%-53.32%
2006-1,587.26%-84.79%
2005-10,435.88%
2003-307.69%318.93%
2002-73.45%-54.28%
2001-160.63%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
24.28%-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
29.90%-99.94%๐Ÿ‡บ๐Ÿ‡ธ USA
22.40%-99.72%๐Ÿ‡บ๐Ÿ‡ธ USA
19.90%-99.94%๐Ÿ‡ซ๐Ÿ‡ท France
-15.56%-99.96%๐Ÿ‡บ๐Ÿ‡ธ USA
-127.92%-99.55%๐Ÿ‡บ๐Ÿ‡ธ USA

What is a company's Operating Margin

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.